4-ethoxy-3,5-dibromo-aniline | 52765-17-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-ethoxy-3,5-dibromo-aniline
• 英文别名: 3.5-Dibrom-p-phenetidin；4-Aethoxy-3,5-dibrom-anilin；2.6-Dibrom-4-amino-phenetol；2.6-Dibrom-4-amino-phenol-aethylaether；3,5-dibromo-4-ethoxy-aniline；3,5-Dibromo-4-ethoxyaniline
• CAS: 52765-17-0
• 化学式: C₈H₉Br₂NO
• 分子量: 294.974
• InChiKey: RVAIEOIDJDTMJC-UHFFFAOYSA-N

物化性质

• 熔点：
  54 °C
• 沸点：
  337.5±37.0 °C(Predicted)
• 密度：
  1.792±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-ethoxy-3,5-dibromo-aniline 在 吡啶 、 sodium hydroxide 作用下， 反应 1.0h， 生成 4-Amino-N-(3,5-dibromo-4-ethoxy-phenyl)-benzenesulfonamide
  参考文献：
  名称：

  Patil, L. S.; Chaudhari, D. T.; Sengupta, S. R., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1994, vol. 33, # 6, p. 607 - 608

  摘要：

  DOI：
• 作为产物：
  描述：

  4-氨基-2,6-二溴苯酚 在 氢氧化钾 、 乙醇 作用下， 生成 4-ethoxy-3,5-dibromo-aniline
  参考文献：
  名称：

  Bargellini, Gazzetta Chimica Italiana, 1930, vol. 60, p. 559,569

  摘要：

  DOI：

文献信息

• [EN] THERAPEUTIC ARYL-AM I DO-ARYL COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS ARYLAMIDOARYLIQUES THÉRAPEUTIQUES ET LEUR UTILISATION
  申请人：KING S COLLEGE LONDON

  公开号：WO2011027106A1

  公开（公告）日：2011-03-10

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-amido-aryl compounds of the following formula (for convenience, collectively referred to herein as "AAA compounds"), which, inter alia, are (selective) retinoic acid receptor α (RARα) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RARα, and in the treatment of diseases and conditions that are mediated by RARα, that are ameliorated by the activation of RARα, etc., including cognitive disorders, memory impairment, memory deficit, senile dementia, Alzheimer's disease, early stage Alzheimer's disease, intermediate stage Alzheimer's disease, late stage Alzheimer's disease, cognitive impairment, and mild cognitive impairment.

  本发明一般涉及治疗化合物领域，更具体地涉及以下结构的某些芳基酰胺-芳基化合物（为方便起见，统称为“AAA化合物”），这些化合物是（选择性的）视黄酸受体α（RARα）激动剂。本发明还涉及包含这种化合物的药物组合物，以及利用这种化合物和组合物在体内外（选择性地）激活RARα，并用于治疗由RARα介导的疾病和症状，通过激活RARα得到改善等方面，包括认知障碍、记忆障碍、记忆缺陷、老年痴呆症、阿尔茨海默病、早期阿尔茨海默病、中期阿尔茨海默病、晚期阿尔茨海默病、认知障碍和轻度认知障碍的治疗。
• Therapeutic Aryl-Amido-Aryl Compounds and Their Use
  申请人：Corcoran Jonathan Patrick Thomas

  公开号：US20120149737A1

  公开（公告）日：2012-06-14

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-amido-aryl compounds of the following formula (for convenience, collectively referred to herein as “AAA compounds”), which, inter alia, are (selective) retinoic acid receptor α (RARα) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RARα, and in the treatment of diseases and conditions that are mediated by RARα, that are ameliorated by the activation of RARα, etc., including cognitive disorders, memory impairment, memory deficit, senile dementia, Alzheimer's disease, early stage Alzheimer's disease, intermediate stage Alzheimer's disease, late stage Alzheimer's disease, cognitive impairment, and mild cognitive impairment.

  本发明涉及治疗化合物领域，更具体地涉及以下公式的某些芳基酰胺-芳基化合物（为方便起见，以下统称为“AAA化合物”），其为（选择性）视黄酸受体α（RARα）激动剂。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物和组合物在体外和体内（选择性地）激活RARα，并用于治疗由RARα介导的疾病和症状，以及通过激活RARα改善的疾病和症状，包括认知障碍、记忆障碍、记忆缺陷、老年性痴呆、阿尔茨海默病、早期阿尔茨海默病、中期阿尔茨海默病、晚期阿尔茨海默病、认知损害和轻度认知损害。
• Therapeutic aryl-amido-aryl compounds and their use
  申请人：King's College London

  公开号：US09447028B2

  公开（公告）日：2016-09-20

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-amido-aryl compounds of the following formula (for convenience, collectively referred to herein as “AAA compounds”), which, inter alia, are (selective) retinoic acid receptor α (RARα) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RARα, and in the treatment of diseases and conditions that are mediated by RARα, that are ameliorated by the activation of RARα, etc., including cognitive disorders, memory impairment, memory deficit, senile dementia, Alzheimer's disease, early stage Alzheimer's disease, intermediate stage Alzheimer's disease, late stage Alzheimer's disease, cognitive impairment, and mild cognitive impairment.

  本发明涉及治疗化合物领域，更具体地涉及以下公式的某些芳基酰胺芳基化合物（方便起见，统称为“AAA化合物”），这些化合物是（选择性）视黄酸受体α（RARα）激动剂。本发明还涉及含有这样的化合物的制药组合物，以及这样的化合物和组合物的使用，无论是体外还是体内，来（选择性地）激活RARα，并治疗由RARα介导的疾病和状况，这些疾病和状况通过激活RARα得到改善等，包括认知障碍、记忆障碍、记忆缺陷、老年性痴呆、阿尔茨海默病、早期阿尔茨海默病、中期阿尔茨海默病、晚期阿尔茨海默病、认知障碍和轻度认知障碍。
• Staedel, Justus Liebigs Annalen der Chemie, 1883, vol. 217, p. 44
  作者：Staedel

  DOI：——

  日期：——
• Bargellini; Monti, Atti della Accademia Nazionale dei Lincei, Classe di Scienze Fisiche, Matematiche e Naturali, Rendiconti, 1930, vol. <6> 11, p. 574,577
  作者：Bargellini、Monti

  DOI：——

  日期：——